VOR · Vor Biopharma Inc.
$22.71
-0.65 (-2.78%)
At close · Aug 24
Market Cap
$1.38B
Shares
59.16M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$695.98M
-495.3%
FY2025
Diluted EPS
-$70.50
-107.2%
FY2025
Operating Cash Flow
-$142.71M
-43.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $76.85M | $321.53M | $93.31M | $94.32M | $64.55M | $47.53M | $31.62M | |
| $70.23M | $50.11M | $27.88M | $31.72M | $28.87M | $21.49M | $11.75M | |
| — | $29.71M | — | — | — | — | — | |
| $147.08M | $371.64M | $121.19M | $126.04M | $93.42M | $69.02M | $43.37M | |
| -$147.08M | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -$69.02M | -$43.37M | |
| $12.8M | $5.87M | $4.27M | $8.17M | $1.32M | $119K | $29K | |
| $774.86M | -$324.34M | $4.27M | $8.17M | $1.32M | $119K | $29K | |
| $627.78M | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.9M | -$43.34M | |
| — | — | — | -$117.86M | -$92.09M | -$70.13M | -$49.26M | |
| $626.84M | -$695.96M | -$116.82M | -$117.17M | -$92.86M | -$70.13M | — | |
| USD/shares | — | -$70.50 | -$34.03 | -$35.00 | -$46.60 | -$42.00 | — |
| USD/shares | — | -$70.50 | -$34.03 | -$35.00 | -$46.60 | -$42.00 | — |
| shares | — | 9.87M | 3.44M | 3.36M | 1.98M | 1.67M | 10.68K |
| shares | — | 9.87M | 3.44M | 3.36M | 1.98M | 1.67M | 10.68K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2025: $0 in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.90×
EV/EBIT
—
Peer median 12.38×
P/E (TTM)
—
Peer median 17.54×
Peer medians compare against the 282 similar-size Biotechnology companies (of 533 listed).
Key facts
CIK
1817229
CUSIP
929033207
13F (30d)
101 filings
98 filers
Visit website
Investor relations